ZymoGenetics Inc has signed an agreement granting Amgen a license to ZymoGenetics' Ig-fusion protein patents. As a result of this agreement, ZymoGenetics and Amgen have terminated the patent infringement lawsuit filed by ZymoGenetics in March 2002 against Immunex Corporation (now owned by Amgen Corporation) for the product Enbrel (etanercept).

Pursuant to the settlement, Amgen, and separately Wyeth, will receive a nonexclusive, worldwide license to ZymoGenetics' patents claiming immunoglobulin fusion proteins, in exchange for a lump sum payment to ZymoGenetics. Further details of the agreement were not disclosed.